TERT启动子多态性rs2853669与NSCLC端粒参数的EGFR突变依赖性关联
该研究基于250例NSCLC术后肿瘤样本,分析TERT启动子SNP rs2853669与TERT mRNA水平、相对端粒长度及预后的关系。结果显示,在无EGFR突变患者中,rs2853669 T/C等位基因与更低的TERT mRNA表达和更短的RTL显著相关,且与最短OS和DFS相关;而在EGFR突变患者中未见此类差异。
要点
- rs2853669 T/C在无EGFR突变NSCLC中与低TERT mRNA和短RTL相关
- T/C等位基因与全队列最短OS和DFS相关,负向预后效应限于无EGFR突变者
- 该SNP可能为端粒酶靶向治疗提供分层线索
核心结论
- TERT启动子区常见SNP rs2853669与无EGFR突变NSCLC患者的端粒参数及生存显著相关。
研究设计与样本
- 研究使用250例NSCLC患者术后肿瘤样本分析rs2853669与TERT mRNA及RTL的关联。
- 患者中位随访57个月(范围2–99个月),评估临床结局。
主要发现
- 在无EGFR突变患者中,rs2853669 T/C等位基因与较低TERT mRNA表达相关(对比C/C和T/T,p均<0.001)。
- 在无EGFR突变患者中,T/C等位基因与较短RTL相关(对比C/C p=0.039,对比T/T p=0.023)。
- 在EGFR突变患者中未观察到上述差异。
- 全队列中,T/C等位基因与最短OS相关(均值61.8 vs 80.9 vs 88.7个月,plog-rank<0.001)。
- 全队列中,T/C等位基因与最短DFS相关(均值78.3 vs 87.9 vs 91.5个月,plog-rank=0.019);分层分析显示T/C对OS的负向预后效应限于无EGFR突变患者。
临床怎么用
- 对无EGFR突变NSCLC患者,可关注rs2853669状态以辅助评估端粒酶相关生物学及预后风险。
- 该SNP可能为端粒酶靶向治疗的患者分层提供参考,但尚需前瞻性验证。
局限性
- 研究基于术后肿瘤样本,样本量250例,结论需外部验证。
- 原文未报告多变量校正结果及机制实验数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The role of epidermal growth factor receptor (EGFR) pathways in regulating telomerase is increasingly being recognised. We analysed the impact of rs2853669 single nucleotide polymorphism (SNP) on telomere parameters and its prognostic value for non-small cell lung cancer (NSCLC) with or without EGFR mutation. METHODS: The association of rs2853669 with telomerase reverse transcriptase (TERT) mRNA level and relative telomere length (RTL) was analysed using resected tumour samples from 250 NSCLC patients. We also investigated the patients' clinical outcomes with a median follow-up of 57 months (2-99 months). RESULTS: The rs2853669 T/C allele was significantly associated with lower TERT mRNA expression (versus C/C and versus T/T; p < 0.001 for both) and shorter RTL (versus C/C and versus T/T; p = 0.039 and 0.023) in patients without EGFR mutation. Such difference was not observed in their counterparts harbouring EGFR mutation. When considering the cohort as a whole, T/C allele was significantly associated with shortest overall survival compared with T/T or C/C allele (mean: 61.8, 80.9 and 88.7 months, plog-rank < 0.001) and disease-free survival (mean: 78.3, 87.9 and 91.5 months, plog-rank = 0.019). Stratification analyses showed that the negative prognostic effect of T/C on OS was constrained in patients without EGFR mutation. CONCLUSION: Our study revealed significant associations of a common SNP within TERT promoter region on telomere parameters and survival in NSCLC patients without EGFR mutation. The result may help providing instruction for therapeutic interventions targeting telomerase and evidence for investigation of TERT-EGFR interacting mechanism in telomere biology.
引用
- Yuan P, Huang S, Bao FC, et al. Discriminating association of a common telomerase reverse transcriptase promoter polymorphism with telomere parameters in non-small cell lung cancer with or without epidermal growth factor receptor mutation. Eur J Cancer. 2019. PMID: 31446212. doi:10.1016/j.ejca.2019.06.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。